The global revcovi (elapegademase-lvlr) market is estimated to grow at a significant CAGR during the forecast period. Revcovi generic name is Elapegademase-Lvlr. Adenosine deaminase severe combined immune deficiency the elapegademase-lVlr (ADA-SCID) is used to treat certain inherited immune system disorders. People with this disorder tend to have repeated and serious or life-threatening infections. Elapegademase-Lvlr is a human-made form in the human body of a substance (adenosine deaminase). It helps to increase the number and fight infection of blood cells (lymphocytes).
A full report of Revcovi Market is available at: https://www.omrglobal.com/industry-reports/revcovi-market
In October 2017, Leadiant Biosciences, Inc. announced that Revcovi (elapegademase-lvlr) injection has been approved by the Food and Drug Administration (FDA). Revcovi is a new enzyme substitute therapy (ERT) for treatment in paediatric patients and the case of adult patients of (ADA-SCID). Later, In October 2018, the FDA approved the drug priority review and Fast Track approval. Additionally, the FDA has designated the drug as an orphan drug.
ADA-SCID is a common genetic disorder that is caused by the mutation into the ADA gene that produces the Adenosine deaminase enzyme. It is also the cause of severe combined immunodeficiency (SCID) in children that affects about one out of every 200,000 newborns globally. Levels, resulting in the death of T- and B-cells. Revcovi (elapegademase-lvlr) drug provides an external source to the adenosine deaminase enzyme ADA enzyme breaks the plasma adenosine that causes accumulated intracellular adenosine to flow outward in the plasma cell.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/revcovi-market
The number of lymphocytes in the blood increases as a result of this. The Revcovi drug is available in a single dose that is a preservative-free sterile and colour free solution injected by the intramuscular route of administration. Revcovi assists the ADA enzyme in its function of removing leftover material from dividing cells. Thus the rising incidence of ADA-SCID is propelling the growth of the market.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segments Covered
o By Type
o By Application
- Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the world
- Competitive Landscape- Leadiant Biosciences., Teijin Pharma Ltd.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Revcovi Market by Segments
By Type
- Pre-filled
- Vial
By Application
- Hospital
- Pharmacy
Company Profiles
- Leadiant Biosciences.
- Teijin Pharma Ltd.
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
